Anthrax future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Anthrax}} | {{Anthrax}} | ||
==Overview== | |||
Given the safety and efficacy of current vaccines and antibiotics, there are not a large number of new agents under development to treat anthrax. | |||
==Newer Agents== | ==Newer Agents== |
Revision as of 20:08, 16 July 2014
Anthrax Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Anthrax future or investigational therapies On the Web |
American Roentgen Ray Society Images of Anthrax future or investigational therapies |
Risk calculators and risk factors for Anthrax future or investigational therapies |
Overview
Given the safety and efficacy of current vaccines and antibiotics, there are not a large number of new agents under development to treat anthrax.
Newer Agents
In May 2009, Human Genome Sciences submitted a Biologic License Application (BLA, permission to market) for its new drug, raxibacumab (brand name ABthrax) intended for emergency treatment of inhaled anthrax.[1]
References
- ↑ "HGSI asks for FDA approval of anthrax drug ABthrax". Forbes. Associated Press. 21 May 2009.[dead link]